Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Osteoporosis International

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-011-1587-0PMID 21374068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

  2011cited by this paper
• Lasofoxifene for postmenopausal women with osteoporosis.

  2010cited by this paper
• Lasofoxifene in postmenopausal women with osteoporosis.

  2010cited by this paper
• Discovery and Synthesis of [6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- 2-(4-hydroxyphenyl)]benzo[b]thiophene: A Novel, Highly Potent, Selective Estrogen Receptor Modulator.

  2010cited by this paper
• Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.

  2009influential reference
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial

  2008cited by this paper
• Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis

  2008cited by this paper
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?

  2007cited by this paper
• Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.

  2007cited by this paper
• Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.

  2007cited by this paper
• Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.

  2005cited by this paper
• Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

  2003cited by this paper
• Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate

  2003cited by this paper
• Effects of raloxifene therapy on the anticoagulant system in postmenopausal women

  2003cited by this paper
• Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

  2002cited by this paper
• Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.

  2002cited by this paper
• The mechanisms of thrombotic risk induced by hormone replacement therapy.

  2001cited by this paper
• Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

  2001cited by this paper
• Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

  1999cited by this paper
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

  1999cited by this paper
• LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.

  1998cited by this paper
• Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.

  1997cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• The quantitative analysis of mammographic densities.

  1994influential reference

• A real‑world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS).

  2024cites this paper
• Insights and implications of sexual dimorphism in osteoporosis

  2024cites this paper
• Microgravity-Related Changes in Bone Density and Treatment Options: A Systematic Review

  2022cites this paper
• Selective Estrogen Receptor Modulators (SERMs)

  2021cites this paper
• Osteoporosis: Mechanism, Molecular Target, and Current Status on Drug Development.

  2020cites this paper
• Stem cells in Osteoporosis: From Biology to New Therapeutic Approaches

  2019cites this paper
• Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

  2019cites this paper
• Selective Estrogen Receptor Modulators (SERMs): State of the Art

  2019cites this paper
• A Novel Strategy to Improve Women’s Health: Selective Estrogen Receptor Modulators

  2018cites this paper
• Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer

  2016cites this paper
• From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).

  2014cites this paper
• Electrochemical oxidation of selective estrogen receptor modulator raloxifene

  2013cites this paper
• Emerging therapies for the treatment of osteoporosis

  2013cites this paper
• Metabolites of Tamoxifen as the Basis of Drug Development

  2013cites this paper
• Regulation of Bone Cell Function by Estrogens

  2013cites this paper
• Nuclear Receptors and Their Selective Pharmacologic Modulators

  2013cites this paper
• Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model

  2013cites this paper
• Raloxifene for the treatment of postmenopausal osteoporosis

  2012cites this paper
• Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass

  2012cites this paper
• Az osteoporosis gyógyszeres kezelése – 2011 = Pharmacologic treatment of osteoporosis – 2011

  2011cites this paper
• Send Orders of Reprints at Reprints@benthamscience.net the Discovery and Development of Selective Estrogen Receptor Modulators (serms) for Clinical Practice the Biological Basis of Serm Action: Target Tissue Specific Actions

  year unknowncites this paper